Correct!
1. Heparin
3. Rivaroxaban
4. 1 or 3

The initial anticoagulant used to treat pulmonary embolism (PE) depends on the patient's situation and may include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), or direct oral anticoagulants (DOACs) such as rivaroxaban (Xarelto®) or apixaban (Eliquis®) (3).
Tissue plasminogen activator (tPA) is not an anticoagulant, but a thrombolytic agent. It is used to dissolve blood clots (thrombi) and restore blood flow in conditions such as: 

• Ischemic stroke (blockage of blood flow to the brain)
• Myocardial infarction (heart attack)
• Hypotensive patients with pulmonary embolism

In patients with acute pulmonary embolism (PE) not associated with hypotension, ACCP guidelines recommend against systemically administered thrombolytic therapy (strong recommendation, low-certainty evidence) (3).

Which of the following are true regarding hereditary thrombophilias? (Click on the correct answer to be directed to the sixth and final page)

1. The most common hereditary thrombophilia in the US is Factor V Leiden
2. Every patient with a DVT should be tested
3. First degree relatives of patients with a hereditary thrombophilia should be tested
4. First degree relatives of patients with a hereditary thrombophilia should be tested before beginning an estrogen-containing contraceptive
5. Genotype-based tests (such as those for Factor V Leiden should not be performed in the first 3 months of a DVT

Home/Critical Care